ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2026
Evidence-based atlas of risk and protective factors for psychotic disorders: an umbrella review to inform personalized prognosis and prevention.
Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An etiological approach to psychosis: potential benefits for treatment, research and prevention.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- How concerns about the naming and the diagnostic concept of "schizophrenia" subtly reinforce each other, and what could be done in this respect.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- External validation and refinement of the Psychosis Polyrisk Score to detect individuals at clinical high risk for psychosis.BMJ mental health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying updated, evidence-based risk and protective factors for psychotic disorders is essential to advancing scientific and clinical knowledge of their etiology. Since the most recent umbrella review published in this journal, the evidence base has expanded substantially. Following a pre-registered protocol, we searched the Web of Science for systematic reviews with meta-analyses of observational studies published between the search date of the last umbrella review (February 1, 2017) and March 31, 2025, examining associations of sociodemographic, parental, perinatal, and later factors or antecedents with ICD/DSM (any version) diagnoses of non-organic psychotic disorders. We graded associations between each putative factor and psychotic disorders using standardized international classification criteria: convincing (class I), highly suggestive (class II), suggestive (class III), and weak (class IV). We also conducted sensitivity analyses: a) lowering the classification criterion requiring more than 1,000 cases to 500 cases, b) restricted to prospective studies (class I-II factors), and c) testing more robust estimates of uncertainty (Hartung-Knapp-Sidik-Jonkman method). Then, we estimated the population attributable fraction (PAF) for potentially modifiable class I-III factors. Study quality was assessed with A MeaSurement Tool to Assess systematic Reviews (AMSTAR). A total of 69 systematic reviews and meta-analyses were included, reporting on 970 individual studies and 221 risk or protective factors for psychotic disorders. Six risk factors showed convincing (class I) evidence of association: Black-African ethnicity in England (odds ratio, OR=4.89, 95% CI: 4.04-5.92), South Asian ethnicity in England (OR=2.15, 95% CI: 1.69-2.73), paternal age <20 years (OR=1.34, 95% CI: 1.20-1.50), birthweight under 2,000 g (OR=1.77, 95% CI: 1.48-2.13), birthweight under 2,500 g (OR=1.50, 95% CI: 1.38-1.64), and maternal history of three or more previous pregnancies (OR=1.32, 95% CI: 1.20-1.45). Eighteen additional factors were highly suggestive (class II): maternal psychosis, Black-Caribbean ethnicity in England, any maternal mental health disorder, ethnic minority status in a low ethnic density area, first-generation immigrant status, cannabis use 5 to 7 days per week, Toxoplasma gondii IgG positivity, history of attention-deficit/hyperactivity disorder (ADHD), trait anhedonia, olfactory identification ability, premorbid IQ, and seven factors pertaining to minor physical anomalies. Two additional factors were upgraded from class IV to class II in our sensitivity analyses: clinical high-risk for psychosis (CHR-P) state, and soft neurological signs. Twenty-six factors (including four protective factors) were suggestive (class III), 75 were weak (class IV), and 96 were non-significant. Sensitivity analyses restricted to prospective studies downgraded some of the above factors, but only total minor physical anomalies became non-significant. The largest PAFs (>10%) were found for childhood adversities (40.69%), Toxoplasma gondii IgG positivity (20.47%), cannabis use 5-7 days per week (12.75%), and CHR-P state (12.68%). The sensitivity analyses employing robust uncertainty estimates confirmed that, among class I factors, Black-African ethnicity in England, birthweight under 2,000 g, and birthweight under 2,500 g retained their level of evidence. The mean AMSTAR score was 7.73 (SD=2.09). These findings provide an evidence-based, updated atlas of risk and protective factors for psychosis, advancing epidemiological knowledge, refining precision psychiatry, identifying targets for preventive intervention, and guiding global public health research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.